Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights in myelodysplastic syndromes (MDS) from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include the APR-246 (NCT03072043) and magrolimab (NCT03248479) trials, as well as studies of IDH inhibitors.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.